Twice-Daily Radiation Linked to Improved Quality of Life in Lung Cancer Trial
Source Summary
The NRG-LU005 trial evaluated adding the immunotherapy drug atezolizumab to standard concurrent chemoradiation for limited-stage small-cell lung cancer. Results presented at the American Society for Radiation Oncology 2024 Annual Meeting showed that atezolizumab did not improve overall survival for this patient population.
Why it matters
The trial results indicate that adding atezolizumab to standard chemoradiation does not extend survival for limited-stage small-cell lung cancer patients, informing treatment decisions for this patient population.
